NCT00495716

Effect of HSV-2 Suppressive Therapy on Sexual Behavior

Effect of Suppressive Therapy on Behavioral Determinants of HSV-2 Transmission

• Status: Terminated
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 72 (actual)
• Sponsor: University of Washington · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine what effect suppressive therapy has on sexual behavior and quality of life among persons with genital herpes (HSV) who have multiple sex partners. Study terminated; investigator relocated and study funding ended. Results were never analyzed because data were not collected.

Detailed description

We plan to conduct a randomized controlled trial of chronic suppressive acyclovir, 400 mg orally twice daily (standard dose) versus episodic acyclovir for treatment of genital herpes recurrences. We will enroll 500 HSV-2 seropositive single persons (250 per arm), stratified by gender and history of symptomatic genital herpes, and prospectively follow them for 1 year to assess sexual behavior, adherence to therapy, and herpes-related quality of life. These outcomes will be measured by self-report in a confidential, computer-based assessment. We plan to use data from this trial to model the effect that increasing the proportion of sexually-active HSV-2 infected persons taking suppressive therapy will have on population-level incidence and prevalence of HSV-2.

Conditions

• Genital Herpes

Interventions

Type	Name	Description
DRUG	acyclovir	800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence
DRUG	acyclovir	400 mg acyclovir orally twice daily for 1 year

Timeline

• Start date: 2008-01-01
• Primary completion: 2010-06-01
• Completion: 2010-06-01
• First posted: 2007-07-03
• Last updated: 2023-03-07
• Results posted: 2020-01-29

Locations

1 site across 1 country: United States